Blog

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).

After reaching the goal of 100,000 veterans cured of hepatitis C virus (HCV) in as few as two months, the Department of Veterans Affairs (VA) now includes in its contract with Echosens the FibroScan® 430 mini+ portable technology.

Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes — more than 30 million people — and another 84 million adults are at high risk of developing Type 2 diabetes.

Stephen Harrison, MD, from Pinnacle Clinical Research, highlights the importance of new treatment options for patients with nonalcoholic steatohepatitis, findings from the REGENERATE clinical trial that were presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting and Postgraduate Course, and more.

Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how to educate patients on nonalcoholic fatty liver disease (NAFLD), lifestyle changes that are crucial for patients with NAFLD, and more.

Physicians and administrators at some of the nation’s leading Federally Qualified Health Centers (FQHCs) now have the ability to quickly and easily assess liver health to better address the NAFLD epidemic

It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world

Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how specialists can help educate primary care physicians (PCPs) more on non-alcoholic fatty liver disease (NAFLD), the importance of PCPs recognizing which individuals with NAFLD can progress to more sever liver disease, and more.

A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.

Stephen Harrison, MD, from Pinnacle Clinical Research, discusses the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the United States, the correlation between NAFLD and obesity, and more.